AN2 Therapeutics to Participate at Upcoming Investor Conferences
Business Wire•20/10/2026•16:13 ET
1
Key Highlights
- ➤AN2 Therapeutics (ANTX) management to attend three investor conferences in November 2026
- ➤CEO Eric Easom scheduled for Guggenheim fireside chat and Stifel corporate overview
- ➤Three Phase 2 studies expected active in 2026, alongside two preclinical candidates
AN2 Therapeutics to Participate at Upcoming Investor Conferences
AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced company management will participate in three upcoming investor conferences in November.
Get started
Create a free account to read the full story.